Skip to content
10-Q

Quarterly Report

TREVI THERAPEUTICS, INC. TRVI

0000950170-25-067011

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 101.74M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $19.37M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $34.1M
Current Liabilities Q1 2025 · Mar 31, 2025 $6.87M
Current Liabilities Q1 2025 · Dec 31, 2024 $10.51M
Total Liabilities Q1 2025 · Mar 31, 2025 $7.55M
Total Liabilities Q1 2025 · Dec 31, 2024 $11.26M
Current Assets Q1 2025 · Mar 31, 2025 $105.62M
Current Assets Q1 2025 · Dec 31, 2024 $109.43M
Total Assets Q1 2025 · Mar 31, 2025 $107M
Total Assets Q1 2025 · Dec 31, 2024 $110.9M
Shares Diluted Q1 2025 · Mar 31, 2024 99.52M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$10.47M
Stockholders Equity Q1 2025 · Mar 31, 2024 $72.33M
Stockholders Equity Q1 2025 · Dec 31, 2023 $82.55M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.11
Eps Basic Q1 2025 · Mar 31, 2024 −$0.11
Sga Expense Q1 2025 · Mar 31, 2024 $3.1M
Rd Expense Q1 2025 · Mar 31, 2024 $8.8M
Net Income Q1 2025 · Mar 31, 2024 −$10.9M
Operating Income Q1 2025 · Mar 31, 2024 −$11.91M